Citerar lösryckta delar ur artikel, citat
The war on Hydroxychloroquine can be traced back to Gilead, the drug maker looking to profit big from Remdesivir
(Natural News) It was beyond strange when the major media networks began to attack a pharmaceutical, especially in the middle of a pandemic. When did the major media networks ever criticize a drug? It turns out that controversial pharmaceutical is a cheap medicine that helps human cells uptake zinc so their immune system can recover from coronavirus infections.
Dr. Didier Raoult of France was using something as simple and cheap as hydroxychloroquine (HCQ) in combination with zinc and an antibiotic to successfully treat coronavirus patients. The news of Raoult’s success spread like wildfire, and U.S. President Donald Trump ultimately promoted the treatment, which acts as both a prophylactic and a therapeutic.
But it doesn’t matter how many doctors successfully treat coronavirus patients using HCQ and zinc. It doesn’t matter what people do in the home to help their immune system through the infection. What matters is drug company profits.
Tens of billions of dollars are on the line as Gilead tries to force dangerous Remdesivir down patient’s throats
There are tens of billions of dollars on the line if doctors are able to use something as cheap as HCQ and zinc to cure patients. Gilead, the maker of Remdesivir, wants to make sure that doctors use their 5-day coronavirus treatment which costs $3,000 per patient. In comparison, a generic dose of HCQ costs anywhere between $10 and $20.
Studies on Gilead’s remdesivir are abysmal, showing adverse events for 102 (66%) of 155 remdesivir recipients. The adverse events were so horrific for remdesivir patients, that 18 (12%) of the patients had to be taken off the drug. As their drug failed, Gilead went to war with a simple treatment protocol that was working.
Gilead’s desperate war against HCQ
Slut citat
Läs hela artikeln och sprid vidare i alla dina nätverk
This entry was posted on söndag, september 6th, 2020 at 10:55 and is filed under Okategoriserat. You can follow any responses to this entry through the RSS 2.0 feed. Responses are currently closed, but you can trackback from your own site.